166 related articles for article (PubMed ID: 3274583)
1. Ex vivo depletion of human bone marrow T lymphocytes by soybean lectin fractionation followed by treatment with an anti-pan-T cell (CD5) ricin A- chain immunotoxin.
Siena S; Villa S; Bonadonna G; Bregni M; Gianni AM
Transplant Proc; 1987 Feb; 19(1 Pt 3):2735-7. PubMed ID: 3274583
[No Abstract] [Full Text] [Related]
2. Specific ex-vivo depletion of human bone marrow T lymphocytes by an anti-pan-T cell (CD5) ricin A-chain immunotoxin.
Siena S; Villa S; Bonadonna G; Bregni M; Gianni AM
Transplantation; 1987 Mar; 43(3):421-6. PubMed ID: 3103275
[TBL] [Abstract][Full Text] [Related]
3. Depletion of bone marrow T-lymphocytes with an anti-CD5 monoclonal immunotoxin (ST-1 immunotoxin): effective prophylaxis for graft-versus-host disease.
Antin JH; Bierer BE; Smith BR; Guinan EC; Provost MM; Ferrara J; Macklis RM; Tarbell NJ; Blythman H; Bouloux C
Prog Clin Biol Res; 1990; 333():207-15. PubMed ID: 1689852
[No Abstract] [Full Text] [Related]
4. Lymphocyte reconstitution in children receiving soybean agglutinin T-depleted bone marrow transplants.
Cowan MJ; McHugh T; Smith W; Wara D; Matthay K; Ablin A; Casavant C; Stites D
Transplant Proc; 1987 Feb; 19(1 Pt 3):2744. PubMed ID: 3274585
[No Abstract] [Full Text] [Related]
5. Haploidentical bone marrow transplantation using soybean agglutinin-processed, T-depleted marrow.
Matthay K; Wara DW; Ablin AJ; Cowan MJ
Transplant Proc; 1987 Feb; 19(1 Pt 3):2678-9. PubMed ID: 3274578
[No Abstract] [Full Text] [Related]
6. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE
Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
[TBL] [Abstract][Full Text] [Related]
7. [Cellular sorting methods in autologous (elimination of residual malignant cells) or allogeneic (T lymphocyte elimination) bone marrow grafts. Clinical pilot studies].
Hervé P; Flesch M
Nouv Rev Fr Hematol (1978); 1986; 28(2):97-105. PubMed ID: 2942838
[TBL] [Abstract][Full Text] [Related]
8. T cell depletion from human bone marrow using magnetic beads.
Knobloch C; Spadinger U; Rueber E; Friedrich W
Bone Marrow Transplant; 1990 Jul; 6(1):21-4. PubMed ID: 2390629
[TBL] [Abstract][Full Text] [Related]
9. T-cell depletion with ricin A-chain T101 in allogeneic bone marrow transplantation to prevent severe graft-versus-host disease.
Fauser AA; Shustik C; Langleben A; Laurent G; Kanz L; Spurll GM; Price G; Ahlgren PD; Cooper BA
Clin Invest Med; 1988 Feb; 11(1):40-6. PubMed ID: 3284672
[TBL] [Abstract][Full Text] [Related]
10. T cell depletion of human bone marrow. Comparison of Campath-1 plus complement, anti-T cell ricin A chain immunotoxin, and soybean agglutinin alone or in combination with sheep erythrocytes or immunomagnetic beads.
Frame JN; Collins NH; Cartagena T; Waldmann H; O'Reilly RJ; Dupont B; Kernan NA
Transplantation; 1989 Jun; 47(6):984-8. PubMed ID: 2660360
[TBL] [Abstract][Full Text] [Related]
11. A new approach to the prevention of graft-versus-host disease using XomaZyme-H65 following histo-incompatible partially T-depleted marrow grafts.
Henslee PJ; Byers VS; Jennings CD; Marciniak E; Thompson JS; Macdonald JS; Romond EH; Messino MJ; Scannon PJ
Transplant Proc; 1989 Feb; 21(1 Pt 3):3004-7. PubMed ID: 2650413
[No Abstract] [Full Text] [Related]
12. T-cell depletion and allogeneic bone marrow transplantation.
O'Reilly RJ
Semin Hematol; 1992 Apr; 29(2 Suppl 1):20-6. PubMed ID: 1615341
[No Abstract] [Full Text] [Related]
13. Prevention of graft-versus-host disease with anti-CD5 ricin A chain immunotoxin after CD3-depleted HLA-nonidentical marrow transplantation in pediatric leukemia patients.
Przepiorka D; Chan KW; Champlin RE; Culbert SJ; Petropoulos D; Ippoliti C; Khouri I; Huh YO; Vreisendorp H; Deisseroth AB
Bone Marrow Transplant; 1995 Dec; 16(6):737-41. PubMed ID: 8750262
[TBL] [Abstract][Full Text] [Related]
14. Comparison of three techniques for the ex vivo elimination of T cells from human bone marrow.
Blazar BR; Quinones RR; Heinitz KJ; Sevenich EA; Filipovich AH
Exp Hematol; 1985 Feb; 13(2):123-8. PubMed ID: 3882442
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of anti-CD5 ricin A chain immunoconjugate for prevention of acute graft-vs.-host disease after HLA-identical marrow transplantation.
Przepiorka D; LeMaistre CF; Huh YO; Luna M; Saria EA; Brown CT; Champlin RE
Ther Immunol; 1994 Apr; 1(2):77-82. PubMed ID: 7584486
[TBL] [Abstract][Full Text] [Related]
16. Combined ex vivo treatment with immunotoxins and mafosfamid: a novel immunochemotherapeutic approach for elimination of neoplastic T cells from autologous marrow grafts.
Uckun FM; Stong RC; Youle RJ; Vallera DA
J Immunol; 1985 May; 134(5):3504-15. PubMed ID: 3884712
[TBL] [Abstract][Full Text] [Related]
17. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation.
Weisdorf D; Filipovich A; McGlave P; Ramsay N; Kersey J; Miller W; Blazar B
Bone Marrow Transplant; 1993 Nov; 12(5):531-6. PubMed ID: 8298565
[TBL] [Abstract][Full Text] [Related]
18. Specific inhibition of in vitro lymphocyte transformation by an anti-pan T cell (gp67) ricin A chain immunotoxin.
Kernan NA; Knowles RW; Burns MJ; Broxmeyer HE; Lu L; Lee HM; Kawahata RT; Scannon PJ; Dupont B
J Immunol; 1984 Jul; 133(1):137-46. PubMed ID: 6609971
[TBL] [Abstract][Full Text] [Related]
19. New technology for the depletion of T cells from soybean lectin agglutinated, HLA-matched bone marrow grafts for leukemia: initial laboratory and clinical results.
Collins NH; Carabasi MH; Bleau S; Jagiello C; Young JW; Castro-Malaspina H; Flomenberg N; Papadopoulos EB; Emanuel D; Gillio A
Prog Clin Biol Res; 1992; 377():427-39. PubMed ID: 1438441
[No Abstract] [Full Text] [Related]
20. Bone marrow purging with immunotoxins for treatment of T cell acute lymphoblastic leukemia (T-ALL).
Vallera DA; Uckun FM
Prog Clin Biol Res; 1990; 333():191-204; discussion 205. PubMed ID: 2308981
[No Abstract] [Full Text] [Related]
[Next] [New Search]
